Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aldeyra TherapeuticsALDX +0.52%29 EV-to-EBIT is -2.63 as of Jul. 14, 2026. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 371 Biotechnology companies, Aldeyra Therapeutics ranks worse than 269541.51% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Aldeyra Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $52.45 Mil.
Aldeyra Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aldeyra Therapeutics EV-to-EBIT Related Terms
Aldeyra Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Aldeyra Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aldeyra Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's EV-to-EBIT falls into.
Aldeyra Therapeutics's current Enterprise Value is $66.93 Mil.
Aldeyra Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aldeyra Therapeutics (ALDX) has a EV-to-EBIT of -2.63 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aldeyra Therapeutics and its competitors. According to the industry distribution chart, Aldeyra Therapeutics ranks #999999 out of 371 companies in the Biotechnology industry.
Is Aldeyra Therapeutics' EV-to-EBIT too high?
Aldeyra Therapeutics' current EV-to-EBIT is -2.63. Based on the distribution chart, Aldeyra Therapeutics ranks #999999 out of 371 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' EV-to-EBIT compare to ONCY and VRCA?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #999999 out of 371 companies for EV-to-EBIT. This places Aldeyra Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 13.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.76, based on 371 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aldeyra Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aldeyra Therapeutics's current EV-to-EBIT is -2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current EV-to-EBIT of -2.63. The current EV-to-EBIT is -2.63. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current EV-to-EBIT is -2.63 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score
Get the complete analysis for ALDX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALDX has been successfully added to your 
